CN102552518A - Application of four traditional Chinese medicines in relieving liver and kidney toxicity - Google Patents
Application of four traditional Chinese medicines in relieving liver and kidney toxicity Download PDFInfo
- Publication number
- CN102552518A CN102552518A CN2011104556484A CN201110455648A CN102552518A CN 102552518 A CN102552518 A CN 102552518A CN 2011104556484 A CN2011104556484 A CN 2011104556484A CN 201110455648 A CN201110455648 A CN 201110455648A CN 102552518 A CN102552518 A CN 102552518A
- Authority
- CN
- China
- Prior art keywords
- cinnabaris
- application
- rhizoma coptidis
- traditional chinese
- chinese medicines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Abstract
The invention belongs to the technical field of medicament, relates to a new application of four traditional Chinese medicines including Chinese angelica, radix rehmanniae, liquorice and rhizoma coptidis, and in particular relates to the application of the four traditional Chinese medicines including Chinese angelica, radix rehmanniae, liquorice and rhizoma coptidis in protecting liver and kidney, and the application of the four traditional Chinese medicines including Chinese angelica, radix rehmanniae, liquorice and rhizoma coptidis in the field of pharmacy in a mixed way or independently as detoxication drugs. Proved by results, the four traditional Chinese medicines including Chinese angelica, radix rehmanniae, liquorice and rhizoma coptidis have a certain protection function on the liver and kidney of rats, and can resist hurt caused by cinnabar and other heavy metals.
Description
Technical field:
The invention belongs to medical technical field; Relate to four flavor Chinese medicine angelicas, Radix Rehmanniae, Radix Glycyrrhizae, the application of Rhizoma Coptidis aspect the Liver and kidney protection, be specifically related to four flavor Chinese medicine angelicas, Radix Rehmanniae, Radix Glycyrrhizae, Rhizoma Coptidis mixing or independent the application as the application of antidote in pharmaceutical field.
Background technology:
Along with people's deepens continuously to Chinese medicine research, and the toxic and side effects of Chinese medicine also more and more is familiar with by people.Some virose Chinese medicines belong to conventional Chinese medicine on the one hand, and like the Cinnabaris of Cinnabar Sedative Pill, Cinnabaris has the pharmacological action of tranquillizing and allaying excitement on the one hand, and Cinnabaris belongs to heavy metal on the other hand, and human body is had certain toxic and side effects.Yet the compatibility of Chinese medicine can effectively reduce the toxic and side effects of toxic medicine originally through historical proof, becomes the new way of exploitation antidote.
Summary of the invention:
The object of the present invention is to provide four flavor Chinese medicine angelica, Radix Rehmanniae, Radix Glycyrrhizaes, Rhizoma Coptidis is used separately or mix the new purposes of use aspect releasing Liver and kidney toxicity.
Experimental technique:
(controlling body weight is 220 ± 10g), and medicinal material extract concentrates back gastric infusion (Cinnabaris: 1.8g/Kg/d, Radix Angelicae Sinensis: 1.8g/Kg/d to raise 7 days in the big mouse cage of male Wistar rat; Radix Rehmanniae: 1.8g/Kg/d; Radix Glycyrrhizae: 0.9g/Kg/d, Rhizoma Coptidis: 2.7 g/Kg/d), collect rat urine every day; Collected altogether 8 days, and collected 12 hours urines every day.Collected immediately and put into-20 ℃ of refrigerators preservations.Last day, blood was got in the abdominal cavity.Urine sample is got supernatant V/V=1:2 adding by volume phosphate buffer (0.2 molLNa
2HPO
4/ 0.2 molLNaH
2PO
4), leave standstill centrifugal 10 min under 10 min., 3000 * g condition, get the upper strata stillnesss of night 500 μ l and place 5 mm nuclear-magnetism pipes, get and add an amount of D behind the supernatant
2O and TSP use AVANCE II 600 MHz type superconduction Fourier transform NMR to measure.
Data show test result through the PLS-DA methods analyst respectively by load factor Fig. 1,3,5,7:
1, individually dosed group of Cinnabaris is compared with blank control group, and citrate, ketoglutaric acid, succinate, trimethyloxamine, hippuric acid, formates, Lactated content reduce in the rat body; The content of taurine, creatine, kreatinin, glycine, 3-hydroxybutyric acid, acetate raises, and prompting gives Cinnabaris separately has certain toxic and side effects to the Liver and kidney of rat.
2, Cinnabaris+Radix Angelicae Sinensis administration group contrasts with giving the Cinnabaris group separately, and citrate, ketoglutaric acid, succinate, trimethyloxamine, hippuric acid, formates, Lactated content raise in the rat body; The content of taurine, creatine, kreatinin, glycine, 3-hydroxybutyric acid reduces, and prompting can resist with the Radix Angelicae Sinensis co-administered and give Cinnabaris separately to the caused toxic and side effects of the Liver and kidney of rat.
3, Cinnabaris+Rhizoma Coptidis administration group contrasts with giving the Cinnabaris group separately, and the content of citrate, ketoglutaric acid, succinate, trimethyloxamine, hippuric acid, formates raises in the rat body; The content of creatine, kreatinin, glycine, 3-hydroxybutyric acid reduces, and prompting can resist with the Rhizoma Coptidis co-administered and give Cinnabaris separately to the caused toxic and side effects of the Liver and kidney of rat.
4, Cinnabaris+Radix Angelicae Sinensis administration group contrasts with giving the Cinnabaris group separately, and citrate, trimethyloxamine, hippuric acid, Lactated content raise in the rat body; The content of taurine, glycine, 3-hydroxybutyric acid reduces, and prompting can resist with the Radix Angelicae Sinensis co-administered and give Cinnabaris separately to the caused toxic and side effects of the Liver and kidney of rat.
5, Cinnabaris+when Radix Glycyrrhizae returns the administration group and gives the contrast of Cinnabaris group separately, the content of citrate, succinate, trimethyloxamine, hippuric acid, formates raises in the rat body; The content of taurine, creatine, kreatinin, glycine, 3-hydroxybutyric acid reduces, and prompting can resist with the Radix Angelicae Sinensis co-administered and give Cinnabaris separately to the caused toxic and side effects of the Liver and kidney of rat.
The result shows that four flavor Chinese medicine angelicas, Radix Rehmanniae, Radix Glycyrrhizae, Rhizoma Coptidis have the certain protection effect for the Liver and kidney of rat, can resist the damage that is caused by heavy metals such as Cinnabaris.
Description of drawings:
Fig. 1 be Cinnabaris and Radix Angelicae Sinensis compatibility use with give separately under the Cinnabaris situation load factor figure to the influence of mice endogenous metabolism product (on) (annotate: numeral is the chemical shift of proton nmr spectra figure on, and the endogenous metabolism product of specific displacement study representative marks on scheming);
Fig. 2 is that Cinnabaris and Radix Angelicae Sinensis compatibility use that (block symbol is represented the Cinnabaris group with giving under the Cinnabaris situation PLS-DA fractional analysis figure (descending) to the influence of mice endogenous metabolism product separately; Diamond symbols is represented blank control group; Circle symbol is represented Cinnabaris+Radix Angelicae Sinensis administration group; Show three groups among the figure obviously in zones of different, explain that three groups metabolism situation is obviously different);
Fig. 3 be Cinnabaris and Radix Rehmanniae compatibility use with give separately under the Cinnabaris situation load factor figure to the influence of mice endogenous metabolism product (on) (annotate: numeral is the chemical shift of proton nmr spectra figure on, and the endogenous metabolism product of specific displacement study representative marks on scheming);
Fig. 4 is that Cinnabaris and Radix Rehmanniae compatibility use that (circle symbol is represented the Cinnabaris group with giving under the Cinnabaris situation PLS-DA fractional analysis figure (descending) to the influence of mice endogenous metabolism product separately; Diamond symbols is represented blank control group; Block symbol is represented Cinnabaris+Radix Rehmanniae administration group; Show three groups among the figure obviously in zones of different, explain that three groups metabolism situation is obviously different);
Fig. 5 be Cinnabaris and Radix Glycyrrhizae compatibility use with give separately under the Cinnabaris situation load factor figure to the influence of mice endogenous metabolism product (on) (annotate: numeral is the chemical shift of proton nmr spectra figure on, and the endogenous metabolism product of specific displacement study representative marks on scheming);
Fig. 6 is that Cinnabaris and Radix Glycyrrhizae compatibility use that (diamond symbols is represented the Cinnabaris group with giving under the Cinnabaris situation PLS-DA fractional analysis figure (descending) to the influence of mice endogenous metabolism product separately; Circle symbol is represented blank control group; Block symbol is represented Cinnabaris+Radix Glycyrrhizae administration group; Show three groups among the figure obviously in zones of different, explain that three groups metabolism situation is obviously different);
Fig. 7 be Cinnabaris and Rhizoma Coptidis compatibility use with give separately under the Cinnabaris situation load factor figure to the influence of mice endogenous metabolism product (on) (annotate: numeral is the chemical shift of proton nmr spectra figure on, and the endogenous metabolism product of specific displacement study representative marks on scheming);
Fig. 8 is that Cinnabaris and Rhizoma Coptidis compatibility use that (diamond symbols is represented the Cinnabaris group with giving under the Cinnabaris situation PLS-DA fractional analysis figure (descending) to the influence of mice endogenous metabolism product separately; Circle symbol is represented blank control group; Block symbol is represented Cinnabaris+Rhizoma Coptidis administration group; Show three groups among the figure obviously in zones of different, explain that three groups metabolism situation is obviously different).
The specific embodiment:
Adopt identical experimental implementation in the experimental technique; Rat blood endogenous metabolism product is carried out partial least square method analyze, shown in accompanying drawing, after giving four flavor Chinese medicines; Administration group data with give Cinnabaris group data separately and compare; Approach blank control group more, same explanation explanation four flavor Chinese medicine angelicas, Radix Rehmanniae, Radix Glycyrrhizae, Rhizoma Coptidis have the certain protection effect for the Liver and kidney of rat, can resist the lesions of liver and kidney that is caused by heavy metals such as Cinnabaris.
Claims (4)
1. four flavor Chinese medicines is characterized in that in the application of removing aspect the Liver and kidney toxicity, described Chinese medicine be Radix Angelicae Sinensis, Radix Rehmanniae, Radix Glycyrrhizae,
Rhizoma Coptidis.
2. based on the described application of claim 1, it is characterized in that the independent or mixing use of described Chinese medicine.
3. application according to claim 2 is characterized in that, described Chinese medicine and other antidote compatibility use.
4. any one described application of claim 1-3 is characterized in that, described Chinese medicine is used the preparation of accepting clinically with pharmaceutically acceptable mixed with excipients preparation separately or with the other drug compatibility.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011104556484A CN102552518A (en) | 2011-12-31 | 2011-12-31 | Application of four traditional Chinese medicines in relieving liver and kidney toxicity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011104556484A CN102552518A (en) | 2011-12-31 | 2011-12-31 | Application of four traditional Chinese medicines in relieving liver and kidney toxicity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102552518A true CN102552518A (en) | 2012-07-11 |
Family
ID=46399973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011104556484A Pending CN102552518A (en) | 2011-12-31 | 2011-12-31 | Application of four traditional Chinese medicines in relieving liver and kidney toxicity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102552518A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103735719A (en) * | 2014-01-12 | 2014-04-23 | 万世凤 | Method for preparing compound coptis root capsule |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1178694A (en) * | 1997-07-10 | 1998-04-15 | 迟经惠 | Medicine for curing uraemia |
| CN1325709A (en) * | 2000-05-25 | 2001-12-12 | 黄亚平 | Capsule for removing heat from liver and detoxicating and its preparing process |
| CN1530100A (en) * | 2003-03-14 | 2004-09-22 | 佰内恩株式会社 | Food containing Angelica sinensis extractive and medicine composition thereof |
| KR100867320B1 (en) * | 2007-04-09 | 2008-11-11 | 대전대학교 산학협력단 | Compositions for protecting liver, or for preventing or treating liver fibrosis or cirrhosis |
| CN101428114A (en) * | 2008-11-06 | 2009-05-13 | 李念 | Medicament for treating chronic hepatitis B, cirrhosis and liver ascites |
| KR20090056383A (en) * | 2007-11-30 | 2009-06-03 | 한국 한의학 연구원 | Composition for prevention or treatment of liver toxicity comprising lactic acid bacteria fermented ssangwhatang |
| KR20110057049A (en) * | 2009-11-23 | 2011-05-31 | 박의신 | Functional Prostatitis Therapeutics |
-
2011
- 2011-12-31 CN CN2011104556484A patent/CN102552518A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1178694A (en) * | 1997-07-10 | 1998-04-15 | 迟经惠 | Medicine for curing uraemia |
| CN1325709A (en) * | 2000-05-25 | 2001-12-12 | 黄亚平 | Capsule for removing heat from liver and detoxicating and its preparing process |
| CN1530100A (en) * | 2003-03-14 | 2004-09-22 | 佰内恩株式会社 | Food containing Angelica sinensis extractive and medicine composition thereof |
| KR100867320B1 (en) * | 2007-04-09 | 2008-11-11 | 대전대학교 산학협력단 | Compositions for protecting liver, or for preventing or treating liver fibrosis or cirrhosis |
| KR20090056383A (en) * | 2007-11-30 | 2009-06-03 | 한국 한의학 연구원 | Composition for prevention or treatment of liver toxicity comprising lactic acid bacteria fermented ssangwhatang |
| CN101428114A (en) * | 2008-11-06 | 2009-05-13 | 李念 | Medicament for treating chronic hepatitis B, cirrhosis and liver ascites |
| KR20110057049A (en) * | 2009-11-23 | 2011-05-31 | 박의신 | Functional Prostatitis Therapeutics |
Non-Patent Citations (6)
| Title |
|---|
| 《光明中医》 20090131 刘名波 辨析中药之"毒性" 第24卷, 第01期 * |
| 刘名波: "辨析中药之"毒性"", 《光明中医》, vol. 24, no. 01, 31 January 2009 (2009-01-31) * |
| 胡道道等: "牛黄清心丸可溶性汞溶出的相关性研究", 《中国药学杂志》, vol. 31, no. 10, 31 October 1996 (1996-10-31) * |
| 赵慧辉等: "配伍生地对关木通中马兜铃酸A含量的影响", 《中国中药杂志》, vol. 32, no. 5, 30 March 2007 (2007-03-30), pages 451 - 451 * |
| 郑庆良: "《民间偏方秘方精选》", 31 October 1990, article "误吞铅粉" * |
| 黄正明等: "《抗肝炎中药现代研究与应用》", 31 January 2006, article "地黄", pages: 114 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103735719A (en) * | 2014-01-12 | 2014-04-23 | 万世凤 | Method for preparing compound coptis root capsule |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wu et al. | Drug–drug interactions of silymarin on the perspective of pharmacokinetics | |
| US8858953B2 (en) | Herbal composition for treating cancer | |
| Yan et al. | Discovery of anti-2019-nCoV agents from Chinese patent drugs via docking screening | |
| Liang et al. | In vitro to in vivo evidence of the inhibitor characteristics of Schisandra lignans toward P-glycoprotein | |
| CN101249118A (en) | Chinese medicine extract and medicine use thereof | |
| CN101632827B (en) | Traditional Chinese medicine composition for treating psoriasis and preparation method thereof | |
| CN102481290A (en) | Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders | |
| Lee et al. | Gastroprokinetic effects of DA-9701, a new prokinetic agent formulated with Pharbitis Semen and Corydalis Tuber | |
| CN102552518A (en) | Application of four traditional Chinese medicines in relieving liver and kidney toxicity | |
| US20230029361A1 (en) | Fagopyrum Nutraceutical Compositions | |
| CN1330328C (en) | Extractive of total saponin of clematis root, prepn. method and pharmaceutical use thereof | |
| CN101244122B (en) | Pharmaceutical combination | |
| CN103463247B (en) | Traditional Chinese medicine for treating hepatitis transaminase increase, and preparation method thereof | |
| CN102526226A (en) | Application of traditional Chinese medicine prescription in aspect of relieving liver and kidney toxicity | |
| CN102406694A (en) | Anti-tumor effective part of traditional Chinese medicine lespedeza as well as preparation method and application thereof | |
| CN102813873A (en) | Traditional Chinese medicine composition for treating mental diseases, and preparation method, application and quality control thereof | |
| US20200215150A1 (en) | Medicine for combined use in cancer treatment | |
| CN101167771A (en) | Application of vinca flower and its extraction in preparing medicine for resisting AIDS | |
| Sárközi et al. | Mineral element content of greater celandine (Chelidonium majus L.) | |
| CN104689088B (en) | A kind of Chinese medicine preparation and preparation method of prevention immunosenescence | |
| Tan et al. | Chinese herbal medicine: a neglected offender for fixed drug eruptions | |
| CN102229640B (en) | Application of triterpenoid saponins compound extracted from anemone taipaiensis | |
| US9192642B1 (en) | Method for reducing liver and kidney damage caused by radiotherapy | |
| CN102225107B (en) | Yixin xuezhikang capsule | |
| Wang et al. | Effect of flavonoid compounds extracted from Iris species in prevention of carbon tetrachloride-induced liver fibrosis in rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120711 |